Want to find out about the disease modifying drugs (DMDs) available to treat multiple sclerosis (MS)? MS Decisions is a guide to the DMDs approved for treating relapsing remitting MS in the UK.

Stem cell therapy for multiple sclerosis (MS) includes autologous haemopoietic stem cell transplant (AHSCT). The aim of AHSCT is to rebuild your body’s immune system so that it no longer attacks your myelin or causes inflammation in your brain and spinal cord.

Lemtrada (alemtuzumab) is a disease modifying drug treatment for relapsing remitting MS. You take Lemtrada as an intravenous infusion (drip) in two treatment courses, twelve months apart.

Mavenclad (cladribine) is a disease modifying drug treatment for active relapsing remitting MS. You take Mavenclad as a pill in two treatment courses, twelve months apart.

Copaxone (glatiramer acetate) is a disease modifying drug treatment for relapsing remitting MS. You self-inject Copaxone under the skin either daily or three times a week.

Brabio (glatiramer acetate) is a disease modifying drug treatment for relapsing remitting MS. You self-inject Brabio under the skin either daily or three times a week.

Zeposia (ozanimod) is a disease modifying drug treatment for active relapsing remitting MS. You take Zeposia as a pill once a day.

Aubagio (teriflunomide) is a disease modifying drug treatment for relapsing remitting multiple sclerosis. You take Aubagio as a pill once a day.

A guide to help people with multiple sclerosis (MS) think through the issues that are involved in choosing a disease modifying drug (DMD).